Form 4: Provectus Biopharmaceuticals CEO Edward Pershing Reports Conversion of Convertible Note into Preferred Stock

CEO Edward Pershing reports the conversion of a convertible promissory note into Series D-1 Convertible Preferred Stock and subsequent conversion into common stock.

Summary

• On February 15, 2025, Edward Pershing, CEO of Provectus Biopharmaceuticals, reported transactions involving derivative securities.
• An 8% unsecured convertible promissory note was converted into 27,989 shares of Series D-1 Convertible Preferred Stock at a price of $2.862 on February 15, 2024.
• These shares of Series D-1 Convertible Preferred Stock were then converted into 279,890 shares of common stock on February 15, 2025.
• Following these transactions, Pershing directly owns 1,827,623 shares of common stock.
• The Series D-1 Convertible Preferred Stock will automatically convert into Common Stock on June 20, 2026, unless earlier converted.

Sentiment

Score: 7

Explanation: The document is a routine disclosure of insider transactions, which is generally neutral. The conversion of debt to equity can be seen as a positive sign of financial health, but it's not a major event.

Future Outlook

The Series D-1 Convertible Preferred Stock will automatically convert into Common Stock on June 20, 2026, unless earlier converted into Common Stock in accordance with the terms of the Certificate of Designation for the Series D-1 Convertible Preferred Stock.

Industry Context

Form 4 filings are standard practice for reporting changes in beneficial ownership by company insiders, providing transparency to investors.

Stakeholder Impact

• The conversion of preferred stock to common stock could dilute existing shareholders' ownership.

Key Dates

Keywords

Form 4, Provectus Biopharmaceuticals, Edward Pershing, Series D-1 Convertible Preferred Stock, Common Stock, Conversion, Beneficial Ownership, PVCT